Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows provided by (used in) operating activities:
Net earnings	$ 1,813.4	$ 304.6	$ 146.2
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	1,062.7	1,039.3	712.4
Biomet merger consideration compensation expense			90.4
Share-based compensation	53.7	57.3	46.4
Goodwill and intangible asset impairment	331.5	30.0
Excess income tax benefit from stock option exercises			(11.8)
Inventory step-up	32.8	323.3	317.8
Gain on divestiture of assets			(19.0)
Debt extinguishment		53.3	22.0
Deferred income tax provision	(1,776.0)	(153.2)	(164.0)
Changes in operating assets and liabilities, net of acquired assets and liabilities
Income taxes	150.2	(10.9)	244.7
Receivables	176.5	(137.8)	(56.1)
Inventories	(122.8)	76.4	(205.4)
Accounts payable and accrued liabilities	(148.2)	28.7	(252.0)
Other assets and liabilities	8.5	21.2	(21.8)
Net cash provided by operating activities	1,582.3	1,632.2	849.8
Cash flows provided by (used in) investing activities:
Additions to instruments	(337.0)	(345.5)	(266.4)
Additions to other property, plant and equipment	(156.0)	(184.7)	(167.7)
Purchases of investments		(1.5)	(214.8)
Sales of investments		286.2	802.9
Proceeds from divestiture of assets			69.9
Business combination investments, net of acquired cash	(4.0)	(421.9)
Investments in other assets	(13.8)	(3.0)	(21.7)
Net cash used in investing activities	(510.8)	(1,691.5)	(7,557.9)
Cash flows provided by (used in) financing activities:
Proceeds from senior notes		1,073.5	7,628.2
Proceeds from multicurrency revolving facility	400.0
Payments on multicurrency revolving facility	(400.0)
Redemption of senior notes	(500.0)	(1,250.0)	(2,762.0)
Proceeds from term loan	192.7	750.0	3,000.0
Payments on term loan	(940.0)	(800.0)	(500.0)
Net (payments) proceeds on other debt	(0.9)	(33.1)	0.1
Dividends paid to stockholders	(193.6)	(188.4)	(157.1)
Proceeds from employee stock compensation plans	145.5	136.6	105.2
Unremitted collections from factoring programs	103.5
Business combination contingent consideration payments	(9.1)
Restricted stock withholdings	(8.3)	(6.3)	(11.1)
Excess income tax benefit from stock option exercises			11.8
Debt issuance costs	(0.3)	(10.0)	(58.4)
Repurchase of common stock		(415.5)	(150.0)
Net cash (used in) provided by financing activities	(1,210.5)	(743.2)	7,106.7
Effect of exchange rates on cash and cash equivalents	29.3	(22.7)	(22.6)
(Decrease) increase in cash and cash equivalents	(109.7)	(825.2)	376.0
Cash and cash equivalents, beginning of year	634.1	1,459.3	1,083.3
Cash and cash equivalents, end of period	$ 524.4	634.1	1,459.3
Biomet [Member]
Cash flows provided by (used in) investing activities:
Business acquisition, net of acquired cash			$ (7,760.1)
LDR Holding Corporation [Member]
Adjustments to reconcile net earnings to net cash provided by operating activities:
Biomet merger consideration compensation expense		24.1
Cash flows provided by (used in) investing activities:
Business acquisition, net of acquired cash		$ (1,021.1)